Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System
DESIGN: This study was carried out in three phases. In Phase I, pan-susceptible strains were tested to establish the minimum inhibitory concentration; in Phase II, mostly resistant strains were tested to determine a critical test concentration; and in Phase III, actual clinical isolates were tested to validate the optimal critical concentrations established in Phases I and II.
RESULTS: The critical concentrations established for seven second-line drugs with the Bactec MGIT 960 system are amikacin 1.0 μg/ml, capreomycin 2.5 μg/ml, kanamycin 2.5 μg/ml, ofloxacin 2.0 μg/ml, moxifloxacin 1.0 μg/ml, ethionamide 5.0 μg/ml and para-amino salicylic acid 4.0 μg/ml.
CONCLUSION: The Bactec MGIT 960 System is an accurate and reliable method for rapid drug susceptibility testing (DST) of Mycobacterium tuberculosis against second-line drugs. In the present study, few of the strains were resistant to fluoroquinolones and further DST for this group is required.
Document Type: Regular Paper
Affiliations: 1: Department of Microbiology, P D Hinduja National Hospital and Medical Research Centre Tertiary Care Hospital, Mumbai, India 2: Becton Dickinson Diagnostic Systems, Becton Dickinson, Mumbai, India 3: Becton Dickinson Diagnostic Systems, Sparks, Maryland, USA
Publication date: 01 December 2008
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites